Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
US4834975A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | May 15, 1985 |
| Grant date | May 30, 1989 |
| Priority date | — |
| Expiry date | May 15, 2005 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/865
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Transformed human lymphocyte cell lines have been produced which secrete human monoclonal antibodies to serotypic determinants on LPS molecules of gram-negative bacteria. These antibodies have been found to be protective against lethal challenges of the homologous bacteria. Pharmaceutical compositions containing these antibodies and their prophylactic and therapeutic use in the management of gram-negative disease in humans are also disclosed. Human lymphocyte cell lines secreting human monoclonal antibodies specifically reacting with Pseudomonas aeruginosa Fisher immunotypes 1 (C5B7), 2 (6F11), 4 (C5D5), 5 (13C1), 6 (5G2) and 7 (8E7) were deposited at the American Type Culture Collection and given A.T.C.C. Accession Nos. CRL 8753, CRL 8562, CRL 8754, CRL 8796, CRL 8797 and CRL 8795, respectively.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.